Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor

Elisa Vigna, Giovanni Pacchiana, Cristina Chiriaco, Simona Cignetto, Lara Fontani, Paolo Michieli, Paolo M. Comoglio

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Due to the key role played in critical sub-populations, Met is considered a relevant therapeutic target for glioblastoma multiforme and lung cancers. The anti-Met DN30 antibody, engineered to a monovalent Fab (Mv-DN30), proved to be a potent antagonist, inducing physical removal of Met receptor from the cell surface. In this study, we designed a gene therapy approach, challenging Mv-DN30 in preclinical models of Met-driven human glioblastoma and lung carcinoma. Mv-DN30 was delivered by a Tet-inducible-bidirectional lentiviral vector. Gene therapy solved the limitations dictated by the short half-life of the low molecular weight form of the antibody. In vitro, upon doxycycline induction, the transgene: (1) drove synthesis and secretion of the correctly assembled Mv-DN30; (2) triggered the displacement of Met receptor from the surface of target cancer cells; (3) suppressed the Met-mediated invasive growth phenotype. Induction of transgene expression in cancer cells - transplanted either subcutaneously or orthotopically in nude mice - resulted in inhibition of tumor growth. Direct Mv-DN30 gene transfer in nude mice, intra-tumor or systemic, was followed by a therapeutic response. These results provide proof of concept for a gene transfer immunotherapy strategy by a Fab fragment and encourage clinical studies targeting Met-driven cancers with Mv-DN30. Key message: Gene transfer allows the continuous in vivo production of therapeutic Fab fragments. Mv-DN30 is an excellent tool for the treatment of Met-driven cancers. Mv-DN30 gene therapy represents an innovative route for Met targeting.

Original languageEnglish
Pages (from-to)65-76
Number of pages12
JournalJournal of Molecular Medicine
Volume92
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Immunoglobulin Fragments
Genetic Therapy
Neoplasms
Immunoglobulin Fab Fragments
Glioblastoma
Transgenes
Nude Mice
Genes
Antibodies
Doxycycline
Cell Surface Receptors
Therapeutics
Growth
Immunotherapy
Half-Life
Lung Neoplasms
Molecular Weight
Carcinoma
Phenotype
Lung

Keywords

  • Antibody
  • Cancer
  • Gene therapy
  • Lentiviral vector
  • Met
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Cite this

Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. / Vigna, Elisa; Pacchiana, Giovanni; Chiriaco, Cristina; Cignetto, Simona; Fontani, Lara; Michieli, Paolo; Comoglio, Paolo M.

In: Journal of Molecular Medicine, Vol. 92, No. 1, 01.2014, p. 65-76.

Research output: Contribution to journalArticle

@article{ace9b9786efc44ed9820204c3cec9f54,
title = "Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor",
abstract = "Due to the key role played in critical sub-populations, Met is considered a relevant therapeutic target for glioblastoma multiforme and lung cancers. The anti-Met DN30 antibody, engineered to a monovalent Fab (Mv-DN30), proved to be a potent antagonist, inducing physical removal of Met receptor from the cell surface. In this study, we designed a gene therapy approach, challenging Mv-DN30 in preclinical models of Met-driven human glioblastoma and lung carcinoma. Mv-DN30 was delivered by a Tet-inducible-bidirectional lentiviral vector. Gene therapy solved the limitations dictated by the short half-life of the low molecular weight form of the antibody. In vitro, upon doxycycline induction, the transgene: (1) drove synthesis and secretion of the correctly assembled Mv-DN30; (2) triggered the displacement of Met receptor from the surface of target cancer cells; (3) suppressed the Met-mediated invasive growth phenotype. Induction of transgene expression in cancer cells - transplanted either subcutaneously or orthotopically in nude mice - resulted in inhibition of tumor growth. Direct Mv-DN30 gene transfer in nude mice, intra-tumor or systemic, was followed by a therapeutic response. These results provide proof of concept for a gene transfer immunotherapy strategy by a Fab fragment and encourage clinical studies targeting Met-driven cancers with Mv-DN30. Key message: Gene transfer allows the continuous in vivo production of therapeutic Fab fragments. Mv-DN30 is an excellent tool for the treatment of Met-driven cancers. Mv-DN30 gene therapy represents an innovative route for Met targeting.",
keywords = "Antibody, Cancer, Gene therapy, Lentiviral vector, Met, Targeted therapy",
author = "Elisa Vigna and Giovanni Pacchiana and Cristina Chiriaco and Simona Cignetto and Lara Fontani and Paolo Michieli and Comoglio, {Paolo M.}",
year = "2014",
month = "1",
doi = "10.1007/s00109-013-1079-0",
language = "English",
volume = "92",
pages = "65--76",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor

AU - Vigna, Elisa

AU - Pacchiana, Giovanni

AU - Chiriaco, Cristina

AU - Cignetto, Simona

AU - Fontani, Lara

AU - Michieli, Paolo

AU - Comoglio, Paolo M.

PY - 2014/1

Y1 - 2014/1

N2 - Due to the key role played in critical sub-populations, Met is considered a relevant therapeutic target for glioblastoma multiforme and lung cancers. The anti-Met DN30 antibody, engineered to a monovalent Fab (Mv-DN30), proved to be a potent antagonist, inducing physical removal of Met receptor from the cell surface. In this study, we designed a gene therapy approach, challenging Mv-DN30 in preclinical models of Met-driven human glioblastoma and lung carcinoma. Mv-DN30 was delivered by a Tet-inducible-bidirectional lentiviral vector. Gene therapy solved the limitations dictated by the short half-life of the low molecular weight form of the antibody. In vitro, upon doxycycline induction, the transgene: (1) drove synthesis and secretion of the correctly assembled Mv-DN30; (2) triggered the displacement of Met receptor from the surface of target cancer cells; (3) suppressed the Met-mediated invasive growth phenotype. Induction of transgene expression in cancer cells - transplanted either subcutaneously or orthotopically in nude mice - resulted in inhibition of tumor growth. Direct Mv-DN30 gene transfer in nude mice, intra-tumor or systemic, was followed by a therapeutic response. These results provide proof of concept for a gene transfer immunotherapy strategy by a Fab fragment and encourage clinical studies targeting Met-driven cancers with Mv-DN30. Key message: Gene transfer allows the continuous in vivo production of therapeutic Fab fragments. Mv-DN30 is an excellent tool for the treatment of Met-driven cancers. Mv-DN30 gene therapy represents an innovative route for Met targeting.

AB - Due to the key role played in critical sub-populations, Met is considered a relevant therapeutic target for glioblastoma multiforme and lung cancers. The anti-Met DN30 antibody, engineered to a monovalent Fab (Mv-DN30), proved to be a potent antagonist, inducing physical removal of Met receptor from the cell surface. In this study, we designed a gene therapy approach, challenging Mv-DN30 in preclinical models of Met-driven human glioblastoma and lung carcinoma. Mv-DN30 was delivered by a Tet-inducible-bidirectional lentiviral vector. Gene therapy solved the limitations dictated by the short half-life of the low molecular weight form of the antibody. In vitro, upon doxycycline induction, the transgene: (1) drove synthesis and secretion of the correctly assembled Mv-DN30; (2) triggered the displacement of Met receptor from the surface of target cancer cells; (3) suppressed the Met-mediated invasive growth phenotype. Induction of transgene expression in cancer cells - transplanted either subcutaneously or orthotopically in nude mice - resulted in inhibition of tumor growth. Direct Mv-DN30 gene transfer in nude mice, intra-tumor or systemic, was followed by a therapeutic response. These results provide proof of concept for a gene transfer immunotherapy strategy by a Fab fragment and encourage clinical studies targeting Met-driven cancers with Mv-DN30. Key message: Gene transfer allows the continuous in vivo production of therapeutic Fab fragments. Mv-DN30 is an excellent tool for the treatment of Met-driven cancers. Mv-DN30 gene therapy represents an innovative route for Met targeting.

KW - Antibody

KW - Cancer

KW - Gene therapy

KW - Lentiviral vector

KW - Met

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84891884307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891884307&partnerID=8YFLogxK

U2 - 10.1007/s00109-013-1079-0

DO - 10.1007/s00109-013-1079-0

M3 - Article

C2 - 24013625

AN - SCOPUS:84891884307

VL - 92

SP - 65

EP - 76

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 1

ER -